MedPace (MEDP) Q1 2026: Cancellations Drive Book-to-Bill Down to 0.88, Clouding Growth Trajectory
MedPace’s Q1 headline is a surge in backlog cancellations, pushing net book-to-bill to its lowest in over a year and raising questions about the CRO’s near-term growth runway. Despite robust revenue expansion and solid win rates, both new bookings and RFP flow softened, while backlog visibility beyond twelve months continues to erode. Investors should focus on how management’s pipeline initiatives and cancellation trends shape the balance between revenue durability and future growth.
Summary
- Backlog Cancellations Accelerate: Elevated cancellation rates are now a central headwind for future growth.
- Pipeline and Win Rate Initiatives: Management is emphasizing opportunity expansion and win rate improvements to offset booking softness.
- Visibility Gap Beyond 12 Months: Declining long-term backlog coverage signals risk to sequential growth into 2027.
Performance Analysis
MedPace delivered double-digit revenue growth, with the quarter’s top line up over 26% year-over-year, yet the underlying business dynamics were less favorable. Net new business awards increased at a similar pace, but the net book-to-bill ratio landed at 0.88—well below the 1.0 threshold typically associated with sustainable backlog replenishment. Backlog conversion remained healthy, with 23.3% of starting backlog turning into revenue, and nearly $2 billion of backlog expected to convert in the next twelve months.
However, the surge in cancellations—now at their highest in over a year—combined with a sequential and year-over-year drop in RFPs (request-for-proposals, a key early indicator of demand), point to a cooling new business environment. EBITDA margins held steady despite higher reimbursable costs, thanks to disciplined employee-related expense management. Cash flow from operations was robust, and the balance sheet remains strong with over $650 million in cash.
- Net Book-to-Bill Compression: The 0.88 ratio reflects both higher cancellations and softer gross bookings, pressuring revenue visibility.
- RFP and Pipeline Softness: Sequential and annual declines in RFPs highlight a demand deceleration, though management stresses opportunity quality over quantity.
- Backlog Coverage Shrinkage: The portion of backlog beyond the next twelve months continues to contract, raising questions about post-2026 growth.
In sum, while financial execution remains strong, the foundation for future growth is under pressure from both internal and external demand dynamics.
Executive Commentary
"Quarter 1 of 2026 saw cancellations rise again, with backlog cancels reaching their highest point in over a year. Net bookings were below the level seen in Q4, but well above those in Q1 2025, with a net book-to-bill ratio of 0.88. RFPs were down in the quarter sequentially and year over year. Initial reward notifications and win rate were strong. We continue to view the quality of opportunity flow as good. While there is nothing we can do to alter our cancellation rate, we are focused on expanding our pipeline of opportunities and have implemented a number of initiatives to improve our win rate."
August Trendle, Chief Executive Officer
"EBITDA margin for the first quarter was 21.1% compared to 21.2% in the prior year period, as the impact of higher reimbursable costs were offset primarily by lower employee-related costs. Our 2026 guidance ranges for revenue, EBITDA, net income, and EPS are unchanged from our prior quarter."
Kevin Brady, Chief Financial Officer
Strategic Positioning
1. Cancellation Risk and Backlog Erosion
Cancellation rates are now a defining risk factor. Management acknowledged that backlog cancellations—especially in oncology and cardiovascular—have become persistently elevated, with no single outsized event but rather a broad-based uptick. This dynamic is directly eroding backlog and compressing book-to-bill, undermining sequential growth potential. Importantly, the CEO conceded that the ongoing decline in backlog coverage beyond twelve months is now a real concern, not just a statistical anomaly.
2. Pipeline and Win Rate Focus
To combat demand softness, MedPace is prioritizing pipeline expansion and win rate improvement. While specifics were withheld for competitive reasons, the CEO stressed that initiatives are underway and already yielding stronger win rates in Q1. The company is betting that a broader, higher-quality pipeline can offset higher cancellation rates and restore backlog growth.
3. Revenue Recognition and Bookings Policy
MedPace’s bookings policy is conservative, only recognizing awards as backlog when trials are truly underway (typically at first patient in). This means the company’s reported bookings and backlog are a lagging indicator of business development activity, with a typical lag of three to five quarters from award to backlog conversion. The pre-backlog pool—authorizations not yet started—grew in Q1, but management does not quantify its size or risk profile.
4. Market Exposure and Customer Mix
MedPace remains strategically focused on biotech and smaller pharma, avoiding the large pharma functional outsourcing model. This keeps the business model nimble but exposes it to higher volatility from biotech funding cycles and M&A activity. Management confirmed that recent cancellations were not driven by M&A, but acknowledged that client acquisitions generally result in future business loss.
5. AI and Operational Efficiency
AI investment is ongoing, but net productivity gains remain years out. Management reiterated that any efficiency benefits from AI will be offset by required investments, and does not expect material cost savings or disruption to the CRO model in the next two years.
Key Considerations
This quarter marks a strategic inflection for MedPace, as strong financial execution is now shadowed by structural growth concerns. Investors must weigh near-term revenue durability against the risk of a longer-term slowdown if cancellations persist and backlog coverage continues to shrink.
Key Considerations:
- Cancellation Rate Acceleration: Persistent, broad-based cancellations are now a top risk to backlog replenishment and future growth.
- Pipeline Expansion as a Mitigant: Management is betting on opportunity flow and improved win rates to offset demand softness, but tangible pipeline growth is not yet visible in backlog metrics.
- Customer Concentration: Top five and top ten customers account for 28% and 37% of revenue, respectively, underscoring potential vulnerability to client-specific events.
- Pass-Through Revenue Dynamics: High pass-through rates (44% of revenue) are expected to moderate as metabolic studies wind down, potentially impacting margin mix.
- Pre-Backlog Visibility: The unquantified but growing pre-backlog pool adds optionality, but its conversion timing and risk profile remain opaque.
Risks
The primary risk is that elevated cancellation rates persist, further eroding backlog and compressing future revenue growth. Additional risks include continued softness in RFP flow, increased competition for biotech business, and the potential for client M&A to disrupt future project awards. Management’s candid acknowledgment of backlog coverage deterioration signals that a sequential growth plateau is now a base case unless pipeline initiatives yield rapid results.
Forward Outlook
For Q2 2026, MedPace guided to:
- Unchanged revenue, EBITDA, net income, and EPS ranges from the prior quarter
- Effective tax rate of 19–20% and interest income of $27.5 million
For full-year 2026, management maintained guidance:
- Revenue, EBITDA, net income, and EPS targets unchanged
Management highlighted several factors that could impact outlook:
- Future cancellations remain a variable that could materially affect guidance
- Backlog conversion and gross bookings must improve to sustain growth beyond the next twelve months
Takeaways
MedPace’s near-term revenue is insulated by robust backlog conversion, but the foundation for future growth has weakened as cancellations and RFP softness take hold. The balance of pipeline expansion versus demand headwinds will determine whether sequential growth resumes or a plateau sets in.
- Cancellation-Driven Backlog Decline: Persistent high cancellations are now a structural headwind, making sequential revenue growth less certain.
- Management’s Response: Pipeline and win rate initiatives are underway, but investors should monitor for evidence of sustained backlog replenishment before confidence in a growth reacceleration is warranted.
- Watch for Pre-Backlog Conversion: The size and conversion rate of the pre-backlog pool will be a key swing factor for future quarters.
Conclusion
MedPace’s Q1 2026 highlights a business at a crossroads: operational and financial discipline persist, yet cancellation-driven backlog erosion is now an explicit risk to future growth. The company’s ability to expand its pipeline and convert pre-backlog into revenue will be decisive for its growth narrative heading into 2027.
Industry Read-Through
MedPace’s experience this quarter is a bellwether for the broader CRO sector, especially those with heavy biotech exposure. Cancellation risk is rising as a sector-wide theme, with demand softness and backlog coverage contraction likely to pressure growth for other mid-cap CROs. The industry’s shift toward more conservative backlog recognition and the lag between award and revenue recognition highlight the importance of pipeline health and risk-adjusted forecasting. Investors in the CRO space should scrutinize backlog composition, cancellation trends, and the quality of pre-backlog pools across peers.